Webinar Date/Time: Thu, Feb 8, 2024 11:00 AM EST
Achieve higher productivity in cell line optimization. Learn how a streamlined middle-down mass spectrometry workflow can improve molecular knowledge in less steps.
Register Free: https://www.biopharminternational.com/bp_w/middle-down-analysis
Event Overview:
In biotherapeutic development, changing cell culture conditions is necessary to enable simpler, faster and more cost-effective drug delivery to patients. These changes, however, can induce cellular stress and adversely impact product quality, creating additional challenges in manufacturing.
Reliable and streamlined workflows to characterize post-translational modifications (PTMs) are necessary to create a comprehensive molecular profile of a biopharmaceutical. Adopting workflows that provide these critical pieces of information with minimal processing steps allows for less labor intensive characterization of PTMs and reduces the risk of introducing artificial PTMs or other undesirable modifications.
Key Learning Objectives:
Who Should Attend:
Speaker:
Hirsh Nanda
Director, Analytical Sciences
J&J Innovative Medicine
Hirsh Nanda is the Director of Analytical Sciences at Johnson & Johnson Innovative Medicines. Hirsh joined J&J in 2015. In his current role, he leads an Analytical Sciences group supporting research and development of biologic therapeutics, including cell line engineering and development. His team performs in-depth mass spectroscopy and biophysical characterization across modalities and next-generation therapies.
Register Free: https://www.biopharminternational.com/bp_w/middle-down-analysis
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
Thermo Fisher Opens Advanced Therapies Collaboration Center in California
April 18th 2025The 6000-square-foot facility will provide cell therapy developers the support they need to transition to CGMP manufacturing, and an expanded footprint of the new center is expected to open in Philadelphia later in 2025.
Teva and Samsung Bioepis Launch Biosimilar Eculizumab in US Market
April 17th 2025Eculizumab-aagh (EPYSQLI) is now available in the US to treat patients living with difficult-to-treat rare diseases such as paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and generalized myasthenia gravis.